These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 1665348

  • 1. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
    Claxton D, Suh SP, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R.
    Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
    [Abstract] [Full Text] [Related]

  • 2. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals.
    Etkin M, Filaccio M, Ellerson D, Suh SP, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA.
    Hum Gene Ther; 1992 Apr; 3(2):137-45. PubMed ID: 1391033
    [Abstract] [Full Text] [Related]

  • 3. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center.
    Hum Gene Ther; 1991 Apr; 2(4):359-76. PubMed ID: 1665350
    [No Abstract] [Full Text] [Related]

  • 4. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M, Maeda H, Hara H, Yamamoto Y, Furuyama J.
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [Abstract] [Full Text] [Related]

  • 5. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
    Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF.
    Blood; 1994 May 15; 83(10):3068-76. PubMed ID: 7514051
    [Abstract] [Full Text] [Related]

  • 6. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R.
    Proc Natl Acad Sci U S A; 1990 Jan 15; 87(2):563-7. PubMed ID: 2405384
    [Abstract] [Full Text] [Related]

  • 7. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 8. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D.
    Blood; 1998 Nov 15; 92(10):3780-92. PubMed ID: 9808572
    [Abstract] [Full Text] [Related]

  • 9. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 15; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 10. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Aug 15; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 11. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E, Krahl R, Thalmeier K, Helbig W.
    Exp Hematol; 1995 Dec 15; 23(14):1649-54. PubMed ID: 8542960
    [Abstract] [Full Text] [Related]

  • 12. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 15; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 13. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.
    Cross NC, Feng L, Bungey J, Goldman JM.
    Leuk Lymphoma; 1993 Jan 15; 11 Suppl 1():39-43. PubMed ID: 8251914
    [Abstract] [Full Text] [Related]

  • 14. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B.
    Leukemia; 1994 May 15; 8(5):776-9. PubMed ID: 7514245
    [Abstract] [Full Text] [Related]

  • 15. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
    Fujie H, Tsuchiya S, Morita S, Itano M, Yambe T, Ohasi Y, Minegishi N, Minegishi M, Satou T, Konno T.
    Leukemia; 1994 Sep 15; 8(9):1592-5. PubMed ID: 8090037
    [Abstract] [Full Text] [Related]

  • 16. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y, Chen YZ, Huang HF, Chen P, Lu LH.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep 15; 35(9):859-63. PubMed ID: 12958661
    [Abstract] [Full Text] [Related]

  • 17. Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.
    Hughes TP, O'Shea P, Morgan G, Martiat P, Goldman JM.
    Bone Marrow Transplant; 1991 Sep 15; 7 Suppl 2():23. PubMed ID: 1878700
    [No Abstract] [Full Text] [Related]

  • 18. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
    Traycoff CM, Srour EF, Dutt P, Fan Y, Cornetta K.
    Leukemia; 1997 Jan 15; 11(1):159-67. PubMed ID: 9001433
    [Abstract] [Full Text] [Related]

  • 19. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
    Zhao RC, McIvor RS, Griffin JD, Verfaillie CM.
    Blood; 1997 Dec 15; 90(12):4687-98. PubMed ID: 9389683
    [Abstract] [Full Text] [Related]

  • 20. Blast crisis in a murine model of chronic myelogenous leukemia.
    Daley GQ, Van Etten RA, Baltimore D.
    Proc Natl Acad Sci U S A; 1991 Dec 15; 88(24):11335-8. PubMed ID: 1763047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.